 ContraFect Corporation CFRX, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents DLAs, including Lysins and Amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has been granted two oral presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases ECCMID to be held from April 18-21, 2020, in Paris, France. The oral presentations include new data demonstrating the ability of the Companys lead compound, exebacase, to resensitize methicillin-resistant Staph aureus MRSA to methicillin-derivatives in an animal model of infective endocarditis. Exebacase is currently being studied in the Pivotal Phase 3 DISRUPT Direct Lysis of Staph aureus Resistant Pathogen Trial study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis. 